Regeneron Has $16 Billion in Net Cash and Trades Near 20 Times Earnings. Is It the Cheapest Big Biotech?
The stock has climbed more than 40% in one year.
Full story
Read the full story at The Motley Fool ↗
Continue reading this story on The Motley Fool, the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.
